BSE Live
Feb 02, 10:13Prev. Close
1168.90
Open Price
1169.50
Bid Price (Qty.)
1178.35 (11)
Offer Price (Qty.)
1179.80 (14)
NSE Live
Feb 02, 10:13Prev. Close
1172.10
Open Price
1172.10
Bid Price (Qty.)
1179.20 (2)
Offer Price (Qty.)
1179.50 (15)
| Key Financial Ratios of Aurobindo Pharma (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
| Per Share Ratios | ||||||
| Basic EPS (Rs.) | 29.97 | 33.35 | 21.00 | 24.83 | 53.13 | |
| Diluted EPS (Rs.) | 29.97 | 33.35 | 21.00 | 24.83 | 53.13 | |
| Cash EPS (Rs.) | 35.19 | 37.70 | 28.43 | 31.92 | 61.46 | |
| Book Value [ExclRevalReserve]/Share (Rs.) | 353.55 | 336.62 | 305.75 | 292.15 | 271.80 | |
| Book Value [InclRevalReserve]/Share (Rs.) | 353.55 | 336.62 | 305.75 | 292.15 | 271.80 | |
| Dividend / Share(Rs.) | 0.00 | 4.50 | 3.00 | 9.00 | 4.00 | |
| Revenue from Operations/Share (Rs.) | 188.25 | 181.70 | 218.34 | 192.65 | 270.07 | |
| PBDIT/Share (Rs.) | 49.68 | 48.47 | 36.95 | 36.60 | 80.38 | |
| PBIT/Share (Rs.) | 44.57 | 44.13 | 29.52 | 29.51 | 72.05 | |
| PBT/Share (Rs.) | 40.61 | 41.01 | 27.55 | 27.95 | 71.57 | |
| Net Profit/Share (Rs.) | 30.08 | 33.35 | 21.00 | 24.83 | 53.13 | |
| Profitability Ratios | ||||||
| PBDIT Margin (%) | 26.39 | 26.67 | 16.92 | 18.99 | 29.76 | |
| PBIT Margin (%) | 23.67 | 24.28 | 13.51 | 15.31 | 26.67 | |
| PBT Margin (%) | 21.57 | 22.57 | 12.61 | 14.50 | 26.49 | |
| Net Profit Margin (%) | 15.97 | 18.35 | 9.61 | 12.88 | 19.67 | |
| Return on Networth / Equity (%) | 8.50 | 9.90 | 6.86 | 8.49 | 19.54 | |
| Return on Capital Employed (%) | 12.27 | 12.98 | 9.47 | 9.92 | 25.69 | |
| Return on Assets (%) | 6.34 | 7.76 | 4.93 | 6.73 | 13.42 | |
| Total Debt/Equity (X) | 0.23 | 0.14 | 0.23 | 0.11 | 0.25 | |
| Asset Turnover Ratio (%) | 0.42 | 0.43 | 0.55 | 0.50 | 0.74 | |
| Liquidity Ratios | ||||||
| Current Ratio (X) | 1.20 | 1.38 | 1.46 | 2.35 | 1.83 | |
| Quick Ratio (X) | 0.83 | 0.93 | 0.84 | 1.55 | 1.12 | |
| Inventory Turnover Ratio (X) | 4.63 | 1.77 | 1.94 | 1.41 | 1.58 | |
| Dividend Payout Ratio (NP) (%) | 0.00 | 13.49 | 35.71 | 18.12 | 7.52 | |
| Dividend Payout Ratio (CP) (%) | 0.00 | 11.93 | 26.38 | 14.10 | 6.50 | |
| Earnings Retention Ratio (%) | 0.00 | 86.51 | 64.29 | 81.88 | 92.48 | |
| Cash Earnings Retention Ratio (%) | 0.00 | 88.07 | 73.62 | 85.90 | 93.50 | |
| Valuation Ratios | ||||||
| Enterprise Value (Cr.) | 71,682.11 | 66,554.38 | 34,360.05 | 40,961.62 | 55,216.93 | |
| EV/Net Operating Revenue (X) | 6.56 | 6.25 | 2.69 | 3.63 | 3.49 | |
| EV/EBITDA (X) | 24.84 | 23.43 | 15.87 | 19.10 | 11.72 | |
| MarketCap/Net Operating Revenue (X) | 6.16 | 6.00 | 2.37 | 3.47 | 3.26 | |
| Retention Ratios (%) | 0.00 | 86.50 | 64.28 | 81.87 | 92.47 | |
| Price/BV (X) | 3.28 | 3.24 | 1.69 | 2.29 | 3.24 | |
| Price/Net Operating Revenue | 6.16 | 6.00 | 2.37 | 3.47 | 3.26 | |
| Earnings Yield | 0.03 | 0.03 | 0.04 | 0.04 | 0.06 |
01.02.2026
Chartist Talk: Sudeep Shah bets on Indus Towers, Nestle India, City Union Bank for Budget day
07.01.2026
02.01.2026
19.12.2025
12.11.2025
Aurobindo Pharm Standalone September 2025 Net Sales at Rs 2,789.72 crore, down 1.23% Y-o-Y
07.11.2025
Aurobindo Pharm Consolidated September 2025 Net Sales at Rs 8,285.70 crore, up 6.28% Y-o-Y
12.08.2025
Aurobindo Pharm Consolidated June 2025 Net Sales at Rs 7,868.14 crore, up 3.98% Y-o-Y
05.08.2025
Aurobindo Pharm Standalone June 2025 Net Sales at Rs 2,848.17 crore, up 15.78% Y-o-Y
14.07.2023
Cipla Q1 PAT seen up 6.1% YoY to Rs. 552.3 cr: Prabhudas Lilladher
14.07.2023
Aurobindo Pharma Q1 PAT seen up 6.1% YoY to Rs. 552.3 cr: Prabhudas Lilladher
13.07.2022
Aurobindo Q1 PAT may dip 26.1% YoY to Rs 568.8 cr: ICICI Direct
08.07.2022
Aurobindo Pharma Q1 PAT may dip 20.7% YoY to Rs 610.7 cr: Prabhudas Lilladher
11.02.2019
Analysts remain positive on Aurobindo Pharma, expect stock to return 8-30% after Q3 earnings
25.08.2018
Pharma Q1 review: Brokerages say performance a mixed bag, but are upbeat on domestic biz
10.08.2017
When Rakesh Jhunjhunwala grilled Aurobindo Pharma top brass after muted Q1 results
24.08.2016
Aurobindo to see growth in H2; capacity constraints continue: PL